Verified April 2026

Akston Biosciences and AKS-562c

Akston Biosciences is one of two companies running cat GLP-1 trials. AKS-562c is a once-weekly injection. Cornell is the trial site.

6 min read·Updated April 26, 2026·By Iacob Pastina

Akston Biosciences is a Beverly, Massachusetts-based biotechnology company developing protein-based therapeutics for both human and veterinary applications. They are one of two companies currently running cat GLP-1 trials. Their candidate, AKS-562c, is a once-weekly GLP-1 Fc-fusion injection being studied at the Cornell University College of Veterinary Medicine. Trial initiation was announced November 2025.

What Is AKS-562c?

AKS-562c is a GLP-1 receptor agonist fused to an Fc fragment — a protein engineering technique that extends drug half-life by binding to FcRn receptors that recycle proteins through the body. The same Fc-fusion approach is used in human-side drugs like dulaglutide (Trulicity). Fc-fusion typically gives once-weekly to once-monthly dosing.

Cornell Trial Design

ElementDetail
SponsorAkston Biosciences
SiteCornell University College of Veterinary Medicine
DrugAKS-562c (GLP-1 Fc-fusion, weekly injection)
Target speciesDomestic cats (overweight or obese)
Cats enrolled70 (option to expand to 140)
Primary observation~3 months
Trial startNovember 2025
Expected readoutMid-to-late 2026

How AKS-562c Compares to OKV-119

AttributeAkston AKS-562cOkava OKV-119
Active moleculeNovel GLP-1 Fc-fusionExenatide (existing GLP-1)
DeliveryWeekly subcutaneous injection6-month subcutaneous implant
Trial siteCornell University Vet CollegeMulti-site veterinary network
Trial cats70 (expandable to 140)≥50
Trial startNovember 2025December 2025
Expected readoutMid-to-late 2026Summer 2026
Repeat dosingWeekly foreverEvery 6 months

Frequently Asked Questions

Where is the Akston cat GLP-1 trial?+
The Cornell University College of Veterinary Medicine in Ithaca, New York. The trial enrolls 70 cats with the option to expand to 140.
How does AKS-562c differ from Okava's OKV-119?+
AKS-562c is a novel GLP-1 Fc-fusion delivered as weekly injections. OKV-119 is an exenatide-releasing implant lasting roughly 6 months. Different molecules, different delivery formats.
When will AKS-562c be available?+
Trial readout expected mid-to-late 2026. FDA submission timeline not publicly announced. Realistic earliest commercial launch for cats: 2028-2029.

Related

Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.

Looking for human GLP-1 medications instead?

Visit GLP-1 Picks → 42 verified telehealth providers